NAPLEX Diabetes Case Practice Questions with Answers

Preparing for the NAPLEX requires more than just memorizing drug classes; it requires the ability to apply clinical knowledge to complex patient scenarios. A NAPLEX Diabetes Case typically involves interpreting laboratory values, assessing comorbidities, and selecting the most appropriate therapeutic intervention based on current clinical guidelines. Mastering these cases is essential for success, as diabetes management is a core competency tested frequently on the exam.

Concept Explanation

A NAPLEX Diabetes Case is a clinical scenario that requires candidates to evaluate a patient's glycemic control, renal function, and cardiovascular risk to determine the optimal pharmacotherapeutic plan. These cases often test your understanding of the American Diabetes Association (ADA) Standards of Care. Key components include calculating insulin dosages, identifying contraindications for oral hypoglycemics (like Metformin in low eGFR), and selecting agents with proven cardiovascular or renal benefits, such as SGLT2 inhibitors or GLP-1 receptor agonists.

To excel in these questions, you must be proficient in the NAPLEX Prep process, which includes recognizing the following parameters:

• Hemoglobin A1c (A1c): The primary marker for long-term glucose control, with a general target of < 7% for most non-pregnant adults.
• Estimated Glomerular Filtration Rate (eGFR): Critical for dosing Metformin and SGLT2 inhibitors.
• Comorbidities: Presence of Atherosclerotic Cardiovascular Disease (ASCVD), Heart Failure (HF), or Chronic Kidney Disease (CKD) dictates the choice of second-line agents.
• Hypoglycemia Risk: Identifying drugs like Sulfonylureas and Insulin that carry higher risks.

If you find specific drug mechanisms challenging, you might want to review NAPLEX Diabetes Medication Practice Questions with Answers for a deeper dive into pharmacology. Additionally, using a tool like the AI Exam Simulator can help you get used to the multi-step nature of these cases.

Solved Examples

Example 1: Insulin Dose Adjustment
Patient RJ is a 70 kg male with Type 1 Diabetes using a basal-bolus regimen. He takes 20 units of Insulin Glargine daily and 5 units of Insulin Lispro before each meal (3 times daily). His blood glucose is consistently 240 mg/dL before lunch, and his target is 120 mg/dL. His Correction Factor (CF) is 40. Calculate the correction dose needed for his lunch bolus.

1. Identify the current glucose and the target glucose: $240 \text{ mg/dL} - 120 \text{ mg/dL} = 120 \text{ mg/dL}$.
2. Use the Correction Factor formula: $\text{Correction Dose} = \frac{ \text{Current BG} - \text{Target BG}}{ \text{Correction Factor}}$.
3. Calculate: $\frac{120}{40} = 3 \text{ units}$.
4. RJ should add 3 units to his usual 5-unit mealtime dose, totaling 8 units for lunch.

Example 2: Selecting Therapy Based on Comorbidities
A 55-year-old female with T2DM (A1c 8.2%) has a history of HFrEF (Heart Failure with reduced Ejection Fraction). She is currently on Metformin 1000 mg BID. What is the most appropriate agent to add?

1. Assess the patient's comorbidities: Heart Failure is present.
2. Consult ADA guidelines: For patients with HF, SGLT2 inhibitors with proven benefit (e.g., Empagliflozin, Dapagliflozin) are preferred.
3. Check contraindications: Ensure eGFR is within the allowable range for the specific SGLT2 inhibitor.
4. The correct choice is an SGLT2 inhibitor.

Example 3: Metformin Contraindication
A patient’s lab results show a Serum Creatinine (SCr) of 1.8 mg/dL and a calculated eGFR of 28 mL/min/1.73m². The patient is currently taking Metformin 500 mg BID. What action should the pharmacist recommend?

1. Identify the eGFR: 28 mL/min/1.73m².
2. Recall Metformin guidelines: Metformin is contraindicated if eGFR is below 30 mL/min/1.73m².
3. Determine the action: Discontinue Metformin immediately to avoid the risk of lactic acidosis.

Practice Questions

1. A 62-year-old male with T2DM, hypertension, and a history of myocardial infarction (MI) has an A1c of 7.9% despite taking Metformin 1000 mg BID. His eGFR is 55 mL/min/1.73m². Which of the following is the most appropriate next step in his therapy?

2. MK is a 28-year-old female (60 kg) newly diagnosed with Type 1 Diabetes. The physician wants to start a weight-based total daily dose (TDD) of insulin at 0.5 units/kg/day using a basal-bolus strategy (50% basal, 50% prandial divided between 3 meals). Calculate her dose of Insulin Aspart per meal.

3. Which diabetes medication class is most likely to cause a patient to develop genital mycotic infections and increased urination?

4. A patient with T2DM and an A1c of 9.5% is being started on a basal-bolus insulin regimen. His Total Daily Dose (TDD) is calculated at 60 units. Using the 1800 Rule, calculate the point-drop in blood glucose expected from 1 unit of rapid-acting insulin (Correction Factor).

5. A 50-year-old patient on Metformin and Glipizide complains of frequent episodes of shakiness, sweating, and confusion in the late afternoon. Which medication is the most likely cause, and what is its mechanism of action?

6. A patient is prescribed Bydureon (Exenatide ER). What is a critical counseling point regarding the administration frequency and the risk of thyroid C-cell tumors?

7. Calculate the Insulin-to-Carbohydrate Ratio (ICR) for a patient using the 500 Rule, assuming their TDD of insulin is 50 units.

8. A patient with an eGFR of 35 mL/min/1.73m² is currently not on any diabetes medications and has an A1c of 8.5%. What is the maximum recommended starting dose of Metformin for this patient?

9. Which GLP-1 receptor agonist is available in an oral formulation?

10. A patient presents with a history of recurrent pancreatitis. Which class of diabetes medications should be avoided in this patient?

Answers & Explanations

1. Answer: Add a GLP-1 receptor agonist or SGLT2 inhibitor. Since the patient has a history of MI (ASCVD), guidelines recommend adding an agent with proven CV benefit regardless of A1c. Options include Dulaglutide, Liraglutide, or Empagliflozin. For more endocrine-specific scenarios, see NAPLEX Endocrine Pharmacology Practice Questions with Answers.
2. Answer: 5 units per meal.
   • $\text{TDD} = 60 \text{ kg} \times 0.5 \text{ units/kg} = 30 \text{ units}$.
   • Prandial dose = 50% of TDD = 15 units.
   • Dose per meal = $15 / 3 = 5 \text{ units}$.
3. Answer: SGLT2 Inhibitors. These drugs (e.g., Canagliflozin) work by inhibiting glucose reabsorption in the proximal tubule of the kidney, leading to glucosuria, which increases the risk of fungal infections and osmotic diuresis.
4. Answer: 30 mg/dL.
   • $\text{Correction Factor} = \frac{1800}{ \text{TDD}}$.
   • $\frac{1800}{60} = 30$.
5. Answer: Glipizide; it stimulates insulin secretion. Sulfonylureas are insulin secretagogues that act independently of blood glucose levels, significantly increasing the risk of hypoglycemia compared to Metformin.
6. Answer: Administer once weekly; contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC). Bydureon is a long-acting GLP-1 agonist with a boxed warning for thyroid C-cell tumors.
7. Answer: 10 grams.
   • $\text{ICR} = \frac{500}{ \text{TDD}}$.
   • $\frac{500}{50} = 10$. This means 1 unit of insulin covers 10 grams of carbohydrates.
8. Answer: 500 mg once daily. For patients with an eGFR between 30-45 mL/min/1.73m², it is recommended to either not start Metformin or, if already taking it, reduce the dose. If starting, the dose should be 50% of the maximum dose or as low as 500 mg to assess tolerance.
9. Answer: Semaglutide (Rybelsus). While most GLP-1 agonists are injectable, Rybelsus is the oral version of Semaglutide, requiring specific administration (30 mins before food/drink with < 4 oz water).
10. Answer: GLP-1 Receptor Agonists or DPP-4 Inhibitors. Both classes have been associated with a potential risk of acute pancreatitis in clinical reports.

1. Which of the following laboratory values is the primary diagnostic criterion for diabetes if found on two separate occasions?

• AFasting Plasma Glucose &ge; 100 mg/dL
• BA1c &ge; 6.5%
• CRandom Plasma Glucose &ge; 140 mg/dL
• DPost-prandial glucose &ge; 160 mg/dL

Frequently Asked Questions

What is the "15-15 Rule" in diabetes management?

The 15-15 Rule is a guideline for treating hypoglycemia where a patient consumes 15 grams of fast-acting carbohydrates and rechecks their blood glucose after 15 minutes. If the blood glucose remains below 70 mg/dL, the process is repeated until levels normalize.

Which diabetes medications can cause weight gain?

Insulin, Sulfonylureas, and Thiazolidinediones (TZDs) are the primary classes associated with weight gain. Conversely, GLP-1 receptor agonists and SGLT2 inhibitors are typically associated with weight loss or are weight-neutral.

How is the eGFR used to determine Metformin dosing?

Metformin is contraindicated if the eGFR is less than 30 mL/min/1.73m². If the eGFR is between 30 and 45 mL/min/1.73m², initiation is not recommended, and existing users should have their dose reduced by half.

What are the symptoms of Diabetic Ketoacidosis (DKA)?

DKA typically presents with polyuria, polydipsia, nausea, vomiting, abdominal pain, and a characteristic "fruity" breath odor due to acetone production. Laboratory findings include hyperglycemia, metabolic acidosis, and the presence of ketones in the blood or urine.

Why are GLP-1 agonists preferred over DPP-4 inhibitors in ASCVD?

GLP-1 receptor agonists like Liraglutide and injectable Semaglutide have demonstrated significant cardiovascular risk reduction in large clinical trials. In contrast, DPP-4 inhibitors are generally considered cardiovascular neutral, though some (like Saxagliptin) may increase the risk of heart failure hospitalization.